IL10 and B-cell chronic lymphocytic leukemia: If ruxolitinib is decreasing IL10 transcription, translation, and signaling in vivo, why do circulating CLL cells express high levels of IL-10 signature genes such as IL10 itself and SOCS3 (Figure 1B and Supplementary Figure 1A) (37)?